A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Metastatic, Gastric or Gastro-oesophageal Junction, Cancer Who Progress Following First Line Therapy and Are Ineligible for Treatment With Trastuzumab by HER2 Status (SAGE)
A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the
Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus
Paclitaxel alone in Patients with Metastatic, Gastric or Gastro-oesophageal Junction, Cancer
who progress following First Line Therapy and are Ineligible for Treatment with trastuzumab
by HER2 Status (SAGE)
Interventional
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Assess of the relative efficacy of AZD8931 plus paclitaxel compared with paclitaxel alone by comparison of the change in tumour size.
at 8 weeks from randomization
No
Serban Ghiorghiu, M. D.
Study Director
Scarborough General Hospital
Japan: Ministry of Health, Labor and Welfare
D0102C00006
NCT01579578
April 2012
March 2013
Name | Location |
---|